PRLD

Prelude Therapeutics Incorporated (PRLD) | Rumor.io

Prelude Therapeutics

PRLD

Attention (50-day avg)0%

Attention rank (50-day avg)#2,369

Bullish sentiment (50-day avg)96%

Price to earnings ratio-3.02

Market capitalization312M

Earnings per share-0.73

Dividend yield (TTM)—

Revenue (annual)12.1M

Net income (annual)-99.5M

Social

What share of all stock conversation is about PRLD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% +0

Jul 28

Prelude Therapeutics' stock jumped ~19.8% driven by positive clinical updates and biotech sector tailwinds, reaching $4.66.
The company's share price rose to a significant double-digit gain for the session, with a notable increase in trading volume.
The stock's rise follows Incyte's decision to discontinue its JAK2 V617F inhibitor INCB160058, potentially boosting Prelude's exclusive option deal for its program PRT12396.

Generated by AI

Sentiment

Of the messages about PRLD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	90.27% +7.71
Bearish	—	—	—	9.73% -7.71

Bullish· Dec 29

Prelude Therapeutics shares surged on strong volume after the company presented positive data at the ASH 2025 conference, bringing promising preclinical results for its MPN program.
The company's JAK2V617F inhibitor and mCALR DAC have shown promising preclinical results, indicating potential for future growth.
The stock has been trending upwards, with some traders targeting a price of $4, suggesting a potential for significant gains.

Bearish· Nov 4

$PRLD's management is seen as incompetent for rushing into a deal with $INCY, potentially missing out on higher returns.
The company's recent news announcements, including the discontinuation of the smarca2 program and the departure of its Chief Medical Officer, have damaged management's credibility and led to a stock price drop.
The stock price is expected to retrace below $1 by the end of the year, with many investors who bought at higher prices potentially losing money.

Generated by AI

Topics

Of the messages about PRLD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	78.8%
Technical Analysis	—	—	0%	12.75%
Analysts	—	—	0%	0.61%
Controversies	—	—	0%	0.46%
Earnings	—	—	0%	1.08%
Macro	—	—	0%	6.3%

Apr 20

Prelude Therapeutics priced a $90M underwritten offering at $4.44/share, led by RA Capital and Soleus Capital.
The company presented preclinical data for its development candidate PRT13722, a first-in-class oral KAT6A degrader, at the AACR 2026 meeting, showing promising results for the treatment of HR+/HER2- breast cancer.
Prelude Therapeutics has a pipeline with ongoing Phase 1 trials, including PRT12396, and expects a runway into Q2 2027, with $106M in cash on hand.

Generated by AI

Community

Of the messages about PRLD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	4.17%	27.63%
Newcomers	—	100%	95.83%	72.37%

Regulars· Mar 15

Prelude Therapeutics has filed its 2022 full-year financial results, reporting a loss of $2.44 per share.
The company has announced a clinical trial collaboration with BeiGene to evaluate PRT2527 in combination with Zanubrutinib in hematologic cancers.
Prelude Therapeutics has entered into a material definitive agreement and has filed its 2022 Form 10-K, which includes its full-year financial results and provides a corporate update.

Newcomers· Jul 28

Newcomers are taking notice of Prelude Therapeutics Incorporated ($PRLD) stock, which has seen a significant gain of ~19.8% driven by positive clinical updates and biotech sector tailwinds.
Some traders are using $PRLD as a swing trade, with one post suggesting a target price of $5.30.
The stock's rising price is also attracting the attention of institutional investors, with Ecor disclosed as a new owner of close to 1 million shares.

Generated by AI

News

JPMorgan initiates Prelude Therapeutics stock at Overweight on drug potential

13d agoInvesting.com

Prelude Therapeutics at H.C. Wainwright conference: pipeline gains momentum

13d agoInvesting.com

Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

WILMINGTON, Del., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the H.C. Wainwright 28th Annual Global Investment Conference, taking place in New York City September 14-16, 2026. On Wednesday, September 16, 2026, at 10:30 a.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, Charles Morris, MBChB, MRCP. Chief Medical Officer, Peggy Scherle,

19d agoYahoo Finance

Prelude Therapeutics: A Prognosis After Year Long Rally (NASDAQ:PRLD)

Prelude Therapeutics has rebounded 500% in 12 months after a $60M option deal with Incyte for its JAK2 inhibitor program. Read why PRLD stock is a Hold.

1mo agoSeeking Alpha

Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

The Company expects to initiate its Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer in the fourth quarter Presented preclinical data demonstrating differentiated profile of PRT13722, at the American Association for Cancer Research (AACR) Annual Meeting 2026 Enrollment continues in Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF) Current cash runway expected into the

1mo agouk.finance.yahoo.com

Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High?

The consensus price target hints at a 58.4% upside potential for Prelude Therapeutics (PRLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

2mo agoYahoo Finance

Also Discussed

Investors talking about PRLD also mention

#	Name	Attention
1	IGMS - IGM Biosciences, Inc.	——
2	Bicycle Therapeutics plc - ADRBCYC	0%0
3	Tharimmune Inc.THAR	0%new
4	Nurix Therapeutics, Inc.NRIX	0%new
5	Foghorn Therapeutics Inc.FHTX	0%new
6	Captivision Inc.CAPT	0%new
7	TuHURA Biosciences, Inc.HURA	0%0
8	Deluxe CorpDLX	0%new
9	Zhongchao Inc. Class A Ordinary SharesZCMD	0%new
10	Rein Therapeutics Inc.RNTX	0%0

Prelude Therapeutics Incorporated

Healthcare
Biotechnology

Prelude Therapeutics Incorporated is a clinical-stage precision oncology company focused on discovering and developing novel medicines for cancer patients with high unmet medical needs. Prelude Therapeutics Incorporated is advancing a pipeline of targeted therapies designed to address genetically defined cancers and other difficult-to-treat tumors. Its current programs include small-molecule candidates aimed at key cancer-driving mechanisms such as JAK2V617F, KAT6A, and SMARCA2, as well as approaches for myeloproliferative neoplasms, myelofibrosis, polycythemia vera, essential thrombocythemia, and breast cancer. The company’s work centers on precision medicine, using selective drug design to improve specificity against validated oncology targets. Prelude Therapeutics Incorporated operates as part of the biotechnology sector and plays a role in translating molecular biology insights into potential treatment options for underserved cancer populations.

Website

Location

175 Innovation Boulevard

Wilmington, DE, 19805

United States

Social

What share of all stock conversation is about PRLD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% +0

Jul 28

Prelude Therapeutics' stock jumped ~19.8% driven by positive clinical updates and biotech sector tailwinds, reaching $4.66.
The company's share price rose to a significant double-digit gain for the session, with a notable increase in trading volume.
The stock's rise follows Incyte's decision to discontinue its JAK2 V617F inhibitor INCB160058, potentially boosting Prelude's exclusive option deal for its program PRT12396.

Generated by AI

Sentiment

Of the messages about PRLD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	90.27% +7.71
Bearish	—	—	—	9.73% -7.71

Bullish· Dec 29

Prelude Therapeutics shares surged on strong volume after the company presented positive data at the ASH 2025 conference, bringing promising preclinical results for its MPN program.
The company's JAK2V617F inhibitor and mCALR DAC have shown promising preclinical results, indicating potential for future growth.
The stock has been trending upwards, with some traders targeting a price of $4, suggesting a potential for significant gains.

Bearish· Nov 4

$PRLD's management is seen as incompetent for rushing into a deal with $INCY, potentially missing out on higher returns.
The company's recent news announcements, including the discontinuation of the smarca2 program and the departure of its Chief Medical Officer, have damaged management's credibility and led to a stock price drop.
The stock price is expected to retrace below $1 by the end of the year, with many investors who bought at higher prices potentially losing money.

Generated by AI

Topics

Of the messages about PRLD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	78.8%
Technical Analysis	—	—	0%	12.75%
Analysts	—	—	0%	0.61%
Controversies	—	—	0%	0.46%
Earnings	—	—	0%	1.08%
Macro	—	—	0%	6.3%

Apr 20

Prelude Therapeutics priced a $90M underwritten offering at $4.44/share, led by RA Capital and Soleus Capital.
The company presented preclinical data for its development candidate PRT13722, a first-in-class oral KAT6A degrader, at the AACR 2026 meeting, showing promising results for the treatment of HR+/HER2- breast cancer.
Prelude Therapeutics has a pipeline with ongoing Phase 1 trials, including PRT12396, and expects a runway into Q2 2027, with $106M in cash on hand.

Generated by AI

Community

Of the messages about PRLD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	4.17%	27.63%
Newcomers	—	100%	95.83%	72.37%

Regulars· Mar 15

Prelude Therapeutics has filed its 2022 full-year financial results, reporting a loss of $2.44 per share.
The company has announced a clinical trial collaboration with BeiGene to evaluate PRT2527 in combination with Zanubrutinib in hematologic cancers.
Prelude Therapeutics has entered into a material definitive agreement and has filed its 2022 Form 10-K, which includes its full-year financial results and provides a corporate update.

Newcomers· Jul 28

Newcomers are taking notice of Prelude Therapeutics Incorporated ($PRLD) stock, which has seen a significant gain of ~19.8% driven by positive clinical updates and biotech sector tailwinds.
Some traders are using $PRLD as a swing trade, with one post suggesting a target price of $5.30.
The stock's rising price is also attracting the attention of institutional investors, with Ecor disclosed as a new owner of close to 1 million shares.

Generated by AI

Prelude Therapeutics

Social

Jul 28

Bullish· Dec 29

Bearish· Nov 4

Apr 20

Regulars· Mar 15

Newcomers· Jul 28

JPMorgan initiates Prelude Therapeutics stock at Overweight on drug potential

Prelude Therapeutics at H.C. Wainwright conference: pipeline gains momentum

Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Prelude Therapeutics: A Prognosis After Year Long Rally (NASDAQ:PRLD)

Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High?

Also Discussed

Prelude Therapeutics Incorporated

Company Information

Location

JPMorgan initiates Prelude Therapeutics stock at Overweight on drug potential

Prelude Therapeutics at H.C. Wainwright conference: pipeline gains momentum

Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Prelude Therapeutics: A Prognosis After Year Long Rally (NASDAQ:PRLD)

Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High?

Also Discussed

Social

Jul 28

Bullish· Dec 29

Bearish· Nov 4

Apr 20

Regulars· Mar 15

Newcomers· Jul 28